Post COVID and Apheresis – Where are we
                    Standing?

Charlotte Steenblock; Romy Walther; Sergey Tselmin; Natalia Jarzebska; Karin Voit-Bak; Nicole Toepfner; Timo Siepmann; Jens Passauer; Christian Hugo; Gloria Wintermann; Ulrich Julius; Mahmoud Barbir; Tina Z. Khan; Milo A. Puhan; Richard Straube; Bernd Hohenstein; Stefan R. Bornstein; Roman N.  Rodionov

doi:10.1055/a-1945-9694

Hormone and Metabolic Research, Inhaltsverzeichnis

Horm Metab Res 2022; 54(11): 715-720
DOI: 10.1055/a-1945-9694

Review

Post COVID and Apheresis – Where are we Standing?

Charlotte Steenblock

¹Department of Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany

,

Romy Walther

¹Department of Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany

,

Sergey Tselmin

¹Department of Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany

,

Natalia Jarzebska

¹Department of Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany

²University Center for Vascular Medicine, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany

,

Karin Voit-Bak

³Zentrum für Apherese- und Hämofiltration am INUS Tagesklinikum, Cham, Germany

,

Nicole Toepfner

⁴Department of Pediatrics, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany

,

Timo Siepmann

⁵Department of Neurology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany

,

Jens Passauer

¹Department of Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany

,

Christian Hugo

¹Department of Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany

,

Gloria Wintermann

⁶Department of Psychotherapy and Psychosomatic Medicine, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany

,

Ulrich Julius

¹Department of Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany

,

Mahmoud Barbir

⁷Department of Cardiology, Harefield Hospital, Harefield, United Kingdom of Great Britain and Northern Ireland

,

Tina Z. Khan

⁷Department of Cardiology, Harefield Hospital, Harefield, United Kingdom of Great Britain and Northern Ireland

,

Milo A. Puhan

⁸Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland

,

Richard Straube

¹Department of Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany

,

Bernd Hohenstein

¹Department of Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany

,

Stefan R. Bornstein

¹Department of Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany

⁹School of Cardiovascular and Metabolic Medicine and Sciences, Faculty of Life Sciences & Medicine, King’s College London, London, United Kingdom of Great Britain and Northern Ireland

,

Roman N. Rodionov

¹Department of Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany

²University Center for Vascular Medicine, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany

› Institutsangaben

Abstract

A continual increase in cases of Long/Post COVID constitutes a medical and socioeconomic challenge to health systems around the globe. While the true extent of this problem cannot yet be fully evaluated, recent data suggest that up to 20% of people with confirmed SARS-CoV-2 suffer from clinically relevant symptoms of Long/Post COVID several weeks to months after the acute phase. The clinical presentation is highly variable with the main symptoms being chronic fatigue, dyspnea, and cognitive symptoms. Extracorporeal apheresis has been suggested to alleviate symptoms of Post/COVID. Thus, numerous patients are currently treated with apheresis. However, at present there is no data from randomized controlled trials available to confirm the efficacy. Therefore, physicians rely on the experience of practitioners and centers performing this treatment. Here, we summarize clinical experience on extracorporeal apheresis in patients with Post/COVID from centers across Germany.

Key words

long COVID - post COVID - apheresis - fatigue - autoantibodies - Immunity

Volltext

Referenzen

References
1 National Institute for Health and Care Excellence: Clinical Guidelines. In, COVID-19 rapid guideline: managing the long-term effects of COVID-19. London: National Institute for Health and Care Excellence (NICE) Copyright NICE. 2020
2 Huang L, Li X, Gu X. et al. Health outcomes in people 2 years after surviving hospitalisation with COVID-19: a longitudinal cohort study. Lancet Respir Med 2022; 10: 863-876
3 Bornstein SR, Cozma D, Kamel M. et al. Long-COVID, metabolic and endocrine disease. Horm Metab Res 2022; 54: 562-566
4 Choutka J, Jansari V, Hornig M. et al. Unexplained post-acute infection syndromes. Nat Med 2022; 28: 911-923
5 Joob B, Wiwanitkit V. Blood viscosity of COVID-19 patient: a preliminary report. Am J Blood Res 2021; 11: 93-95
6 Kubánková M, Hohberger B, Hoffmanns J. et al. Physical phenotype of blood cells is altered in COVID-19. Biophys J 2021; 120: 2838-2847
7 Kanczkowski W, Beuschlein F, Bornstein SR. Is there a role for the adrenal glands in long COVID?. Nat Rev Endocrinol 2022; 18: 451-452
8 Kanczkowski W, Evert K, Stadtmuller M. et al. COVID-19 targets human adrenal glands. Lancet Diabetes Endocrinol 2022; 10: 13-16
9 Paul T, Ledderose S, Bartsch H. et al. Adrenal tropism of SARS-CoV-2 and adrenal findings in a post-mortem case series of patients with severe fatal COVID-19. Nat Commun 2022; 13: 1589
10 Bornstein SR, Voit-Bak K, Donate T. et al. Chronic post-COVID-19 syndrome and chronic fatigue syndrome: Is there a role for extracorporeal apheresis?. Mol Psychiatry 2022; 27: 34-37
11 Abbasi K. Long covid and apheresis: a miracle cure sold on a hypothesis of hope. BMJ 2022; 378: o1733
12 Davies M. Long covid patients travel abroad for expensive and experimental “blood washing”. BMJ 2022; 378: o1671
13 Bechmann N, Barthel A, Schedl A. et al. Sexual dimorphism in COVID-19: potential clinical and public health implications. Lancet Diabetes Endocrinol 2022; 10: 221-230
14 Torjesen I. Covid-19: Middle aged women face greater risk of debilitating long term symptoms. BMJ 2021; 372: n829
15 Honigsbaum M. “An inexpressible dread”: psychoses of influenza at fin-de-siècle. The Lancet 2013; 381: 988-989
16 Stefano GB. Historical insight into infections and disorders associated with neurological and psychiatric sequelae similar to long COVID. Med Sci Monit 2021; 27: e931447
17 Poenaru S, Abdallah SJ, Corrales-Medina V. et al. COVID-19 and post-infectious myalgic encephalomyelitis/chronic fatigue syndrome: a narrative review. Ther Adv Infect Dis 2021; 8 20499361211009385
18 Steenblock C, Schwarz PEH, Perakakis N. et al. The interface of COVID-19, diabetes, and depression. Discov Ment Health 2022; 2: 5
19 Sotzny F, Blanco J, Capelli E. et al. Myalgic encephalomyelitis/chronic fatigue syndrome – evidence for an autoimmune disease. Autoimmun Rev 2018; 17: 601-609
20 Berger G. Escape of pathogens from the host immune response by mutations and mimicry. Possible means to improve vaccine performance. Med Hypotheses 2015; 85: 664-669
21 Segal Y, Shoenfeld Y. Vaccine-induced autoimmunity: the role of molecular mimicry and immune crossreaction. Cell Mol Immunol 2018; 15: 586-594
22 Loebel M, Grabowski P, Heidecke H. et al. Antibodies to beta adrenergic and muscarinic cholinergic receptors in patients with chronic fatigue syndrome. Brain Behav Immun 2016; 52: 32-39
23 Danilenko OV, Gavrilova NY, Churilov LP. Chronic fatigue exhibits heterogeneous autoimmunity characteristics which reflect etiology. Pathophysiology 2022; 29: 187-199
24 Fluge Ø, Bruland O, Risa K. et al. Benefit from B-lymphocyte depletion using the anti-CD20 antibody rituximab in chronic fatigue syndrome. A double-blind and placebo-controlled study. PLoS One 2011; 6: e26358
25 Fluge Ø, Risa K, Lunde S. et al. B-Lymphocyte depletion in myalgic encephalopathy/chronic fatigue syndrome. An open-label phase II study with rituximab maintenance treatment. PLoS One 2015; 10: e0129898
26 Fluge Ø, Rekeland IG, Lien K. et al. B-Lymphocyte depletion in patients with myalgic encephalomyelitis/chronic fatigue syndrome: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2019; 170: 585-593
27 Angileri F, Legare S, Marino Gammazza A. et al. Molecular mimicry may explain multi-organ damage in COVID-19. Autoimmun Rev 2020; 19: 102591
28 Mobasheri L, Nasirpour MH, Masoumi E. et al. SARS-CoV-2 triggering autoimmune diseases. Cytokine 2022; 154: 155873
29 Lucchese G, Floel A. Molecular mimicry between SARS-CoV-2 and respiratory pacemaker neurons. Autoimmun Rev 2020; 19: 102556
30 Bastard P, Rosen LB, Zhang Q. et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science 2020; 370 eabd4585
31 Koning R, Bastard P, Casanova JL. et al. Autoantibodies against type I interferons are associated with multi-organ failure in COVID-19 patients. Intensive Care Med 2021; 47: 704-706
32 Troya J, Bastard P, Planas-Serra L. et al. Neutralizing autoantibodies to type I IFNs in>10% of patients with severe COVID-19 pneumonia hospitalized in Madrid, Spain. J Clin Immunol 2021; 41: 914-922
33 Byrne CJ, Khurana S, Kumar A. et al. Inflammatory signaling in hypertension: regulation of adrenal catecholamine biosynthesis. Front Endocrinol (Lausanne) 2018; 9: 343
34 Wallukat G, Hohberger B, Wenzel K. et al. Functional autoantibodies against G-protein coupled receptors in patients with persistent Long-COVID-19 symptoms. J Transl Autoimmun 2021; 4: 100100
35 Bynke A, Julin P, Gottfries CG. et al. Autoantibodies to beta-adrenergic and muscarinic cholinergic receptors in myalgic encephalomyelitis (ME) patients - A validation study in plasma and cerebrospinal fluid from two Swedish cohorts. Brain Behav Immun Health 2020; 7: 100107
36 Hraiech S, Bonnardel E, Guervilly C. et al. Herpes simplex virus and cytomegalovirus reactivation among severe ARDS patients under veno-venous ECMO. Ann Intensive Care 2019; 9: 142
37 Imlay H, Dasgupta S, Boeckh M. et al. Risk factors for cytomegalovirus reactivation and association with outcomes in critically ill adults with sepsis: a pooled analysis of prospective studies. J Infect Dis 2021; 223: 2108-2112
38 Imlay H, Limaye AP. Current understanding of cytomegalovirus reactivation in critical illness. J Infect Dis 2020; 221: S94-S102
39 Libert N, Bigaillon C, Chargari C. et al. Epstein-Barr virus reactivation in critically ill immunocompetent patients. Biomed J 2015; 38: 70-76
40 Gatto I, Biagioni E, Coloretti I. et al. Cytomegalovirus blood reactivation in COVID-19 critically ill patients: risk factors and impact on mortality. Intensive Care Med 2022; 48: 706-713
41 Meng M, Zhang S, Dong X. et al. COVID-19 associated EBV reactivation and effects of ganciclovir treatment. Immun Inflamm Dis 2022; 10: e597
42 Zubchenko S, Kril I, Nadizhko O. et al. Herpesvirus infections and post-COVID-19 manifestations: a pilot observational study. Rheumatol Int 2022; 42: 1523-1530
43 Aldhaleei WA, Alnuaimi A, Bhagavathula AS. COVID-19 Induced hepatitis B virus reactivation: a novel case from the United Arab Emirates. Cureus 2020; 12: e8645
44 Rodríguez-Tajes S, Miralpeix A, Costa J. et al. Low risk of hepatitis B reactivation in patients with severe COVID-19 who receive immunosuppressive therapy. J Viral Hepat 2021; 28: 89-94
45 Shariq M, Sheikh JA, Quadir N. et al. COVID-19 and tuberculosis: the double whammy of respiratory pathogens. Eur Respir Rev 2022; 31: 210264
46 Walitt B, Johnson TP. The pathogenesis of neurologic symptoms of the postacute sequelae of severe acute respiratory syndrome coronavirus 2 infection. Curr Opin Neurol 2022; 35: 384-391
47 Al-Kuraishy HM, Al-Gareeb AI, El-Bouseary MM. et al. Hyperviscosity syndrome in COVID-19 and related vaccines: exploring of uncertainties. Clin Exp Med 2022; 1-10
48 Preiser JC. Oxidative stress. JPEN J Parenter Enteral Nutr 2012; 36: 147-154
49 Carr AC, Maggini S. Vitamin C and immune function. Nutrients 2017; 9: 1211
50 Jensen IJ, McGonagill PW, Berton RR. et al. Prolonged reactive oxygen species production following septic insult. Immunohorizons 2021; 5: 477-488
51 Vollbracht C, Kraft K. Feasibility of vitamin C in the treatment of post viral fatigue with focus on long COVID, based on a systematic review of IV vitamin C on fatigue. Nutrients 2021; 13: 1154
52 Pierce JD, Shen Q, Cintron SA. et al. Post-COVID-19 syndrome. Nurs Res 2022; 71: 164-174
53 Crook H, Raza S, Nowell J. et al. Long covid-mechanisms, risk factors, and management. BMJ 2021; 374: n1648
54 Matta J, Wiernik E, Robineau O. et al. Association of self-reported COVID-19 infection and SARS-CoV-2 serology test results with persistent physical symptoms among French adults during the COVID-19 pandemic. JAMA Intern Med 2022; 182: 19-25
55 Yang C, Zhao H, Tebbutt SJ. A glimpse into long COVID and symptoms. Lancet Respir Med 2022; 10: e81
56 Julius U. History of lipidology and lipoprotein apheresis. Atheroscler Suppl 2017; 30: 1-8
57 Julius U, Parhofer KG, Heibges A. et al. Dextran-sulfate-adsorption of atherosclerotic lipoproteins from whole blood or separated plasma for lipid-apheresis-comparison of performance characteristics with DALI and lipidfiltration. J Clin Apher 2007; 22: 215-223
58 Straube R, Muller G, Voit-Bak K. et al. Metabolic and non-metabolic peripheral neuropathy: is there a place for therapeutic apheresis?. Horm Metab Res 2019; 51: 779-784
59 Zanetti M, Zenti M, Barazzoni R. et al. HELP LDL apheresis reduces plasma pentraxin 3 in familial hypercholesterolemia. PLoS One 2014; 9: e101290
60 Kopprasch S, Bornstein SR, Schwarz PE. et al. Single whole blood dextran sulfate adsorption favorably affects systemic oxidative balance in lipoprotein apheresis patients. Atheroscler Suppl 2013; 14: 157-160
61 Kopprasch S, Graessler J, Bornstein SR. Beyond lowering circulating LDL: apheresis-induced changes of systemic oxidative stress markers by four different techniques. Atheroscler Suppl 2009; 10: 34-38
62 Grassler J, Kopprasch S, Passauer J. Differential effects of lipoprotein apheresis by lipidfiltration or dextran sulfate adsorption on lipidomic profile. Atheroscler Suppl 2013; 14: 151-155
63 Julius U, Siegert G, Kostka H. et al. Effects of different lipoprotein apheresis methods on serum protein levels. Atheroscler Suppl 2015; 18: 95-102
64 Yin X, Takov K, Straube R. et al. Precision medicine approach for cardiometabolic risk factors in therapeutic apheresis. Horm Metab Res 2022; 54: 238-249
65 Hohenstein B, Passauer J, Ziemssen T. et al. Immunoadsorption with regenerating systems in neurological disorders – A single center experience. Atheroscler Suppl 2015; 18: 119-123